CHICAGO (

TheStreet

) --The

American Society of Clinical Oncology

(ASCO) annual meeting kicked into high gear on Saturday. For investors, data presentations of note Saturday came from drugs developed by

Exelixis

(EXEL) - Get Report

,

Celgene

(CELG) - Get Report

,

Nektar Therapeutics

(NKTR) - Get Report

,

Oxigene

(OXGN)

and

Synta Pharmaceuticals

(SNTA)

.

ASCO itself held a media briefing this morning to discuss women's cancers, which will include data on

Roche's

Avastin in ovarian cancer. This afternoon, ASCO held another press briefing at which previously unreleased results from a phase III study of

Incyte's

(INCY) - Get Report

ruxolitinib in myelofibrosis will be released. These data followed Friday's presentation of early-stage data from

YM BioSciences'

( YMI) competing myelofibrosis drug.

Dendreon

(DNDN)

,

Curis

(CRIS) - Get Report

,

Seattle Genetics

(SGEN) - Get Report

and

Medivation

(MDVN)

are all holding off-site investor events this evening.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein

.

>To follow the writer on Twitter, go to

http://twitter.com/adamfeuerstein

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.